Long title
A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
Date receipt dossier
EU record number
MB-CART2019.1
EudraCT number
2018-001253-27
Company / Sponsor
Miltenyi Biotech GmbH
Phase
I/II a
Treated organism
Humans
Indication category
Cancer therapy
Disease
relapsed and resistant B-NHL
Therapeutic approach
Immunotherapy
Genetic modification
CD19 and CD20 chimeric antigen receptor
Method of transfer of nucleic acid of interest
lentiviral vectors
Administered biological material
Autologous T-cells transduced with lentiviral vectors expressing CD19/CD20 CAR
Route of administration
Intravenous
Locations in Belgium
UZ Gent, Cliniques universitaires Saint-Luc
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
MB-CART2019.1